Search hospitals > Illinois > Peru
Illinois CancerCare-Peru
Claim this profilePeru, Illinois 61354
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Non-Small Cell Lung Cancer
385 reported clinical trials
2 medical researchers
Summary
Illinois CancerCare-Peru is a medical facility located in Peru, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Illinois CancerCare-Peru is involved with conducting 385 clinical trials across 477 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Bryan A. FallerCrossroads Cancer Center2 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
226 reported clinical trials
291 drugs studied
James L. WadeDecatur Memorial Hospital3 years of reported clinical research
Studies Recurrence
Studies Breast Cancer
11 reported clinical trials
20 drugs studied
Clinical Trials running at Illinois CancerCare-Peru
Breast Cancer
Prostate Cancer
Cancer
Gastric Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Gastroesophageal Junction Adenocarcinoma
Esophageal Cancer
Esophageal Adenocarcinoma
Bladder Cancer
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Illinois CancerCare-Peru?
Illinois CancerCare-Peru is a medical facility located in Peru, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Illinois CancerCare-Peru is involved with conducting 385 clinical trials across 477 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.
Where is Illinois CancerCare-Peru located?
**Illinois CancerCare - Peru Location**
- **Address:** 4391 Venture Dr, Suite 1, Peru, IL 61354
- **Part of:** Valley Regional Cancer Center
- **Contact:** For more information, visit their website or call (815) 223-7010.
Who should I call to ask about financial aid or insurance network?
For inquiries about financial assistance and insurance matters at Illinois CancerCare-Peru, please contact the main line at (217) 383-3311. The Illinois CancerCare Foundation also provides financial assistance for tumor sequencing and targeted oral therapies for eligible patients.
What insurance does Illinois CancerCare-Peru accept?
Illinois CancerCare-Peru accepts a wide range of insurance plans, including but not limited to Medicare, Aetna (HMO, PPO, POS), BCBS of Illinois (PPO, POS, EPO, Classic Blue HMO, HMOI, Blue Advantage HMO), Beech Street PPO, Cigna/Great West Healthcare (HMO, PPO, POS, Open Access), and United Health Care. It is crucial to confirm that your physicians are within your plan's network. Additionally, pre-certification may be required for those in an HMO or PPO plan.
What awards or recognition has Illinois CancerCare-Peru received?
Illinois CancerCare-Peru, located in Peru, Illinois, is nationally recognized for its excellence in clinical research, being one of the top enrollers for the Alliance for Clinical Trials in Oncology in 2015. Additionally, it has earned certification from the Quality Oncology Practice Initiative (QOPI®) for meeting stringent national standards in cancer care.